Freenome (FRNM) Stock Analysis

What Freenome does

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).

Key metrics

ETFs linked to FRNM

Broad-market and Healthcare sector ETFs an investor holding Freenome is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how FRNM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Freenome?

Freenome trades under the ticker FRNM on NASDAQ.

Which exchange is FRNM listed on?

FRNM is listed on NASDAQ.

What sector does Freenome operate in?

Freenome is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze FRNM in a portfolio?

PortView shows FRNM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.